Clinical trials in Clichy – page 154

3 418 clinical trials in Clichy, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in FranceEssaisCliniques.fr

Clichy at a glance

3 418

clinical trials

Research sites1

Quick filters

3 418 trials in Clichy

Open in trial search

Hepatocellular carcinoma

Not recruiting

Study of Atezolizumab with Lenvatinib or Sorafenib vs Lenvatinib or Sorafenib alone in Unresectable Hepatocellular Carcinoma after Atezolizumab and Bevacizumab

Registered drugNo placebo

Study of Atezolizumab with Lenvatinib or Sorafenib vs Lenvatinib or Sorafenib alone in Unresectable Hepatocellular Carcinoma after Atezolizumab and Bevacizumab

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Atezolizumab
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Dermatomyositis+3

Not recruiting

Phase 2 Study of Daxdilimab with Prednisone in Adults with Inadequately Controlled Dermatomyositis or Anti‑Synthetase Inflammatory Myositis

Registered drug

Phase 2 Study of Daxdilimab with Prednisone in Adults with Inadequately Controlled Dermatomyositis or Anti‑Synthetase Inflammatory Myositis

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Prednisone
Sponsor:Horizon Therapeutics Ireland Designated Activity Company

Contact Research Centre

Colorectal cancer

Not recruiting

Study of denikitug alone or in drug combination in adults with advanced microsatellite stable colorectal cancer

Registered drugNo placebo

Study of denikitug alone or in drug combination in adults with advanced microsatellite stable colorectal cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Gilead Sciences Inc.

Contact Research Centre

Non-small cell lung cancer

Not recruiting

Continuation study of JDQ443 in patients with KRAS G12C‑mutated non‑small cell lung cancer receiving JDQ443 as monotherapy or drug combination

Registered drugNo placebo

Continuation study of JDQ443 in patients with KRAS G12C‑mutated non‑small cell lung cancer receiving JDQ443 as monotherapy or drug combination

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Cetuximab
Sponsor:Novartis Pharma AG

Contact Research Centre

Breast cancer

Not recruiting

Study of alpelisib with trastuzumab and pertuzumab as maintenance therapy in adult patients with HER2‑positive advanced breast cancer and PIK3CA mutation

Registered drugNo placebo

Study of alpelisib with trastuzumab and pertuzumab as maintenance therapy in adult patients with HER2‑positive advanced breast cancer and PIK3CA mutation

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Alpelisib
Sponsor:Novartis Pharma AG

Contact Research Centre

Breast cancer+2

Not recruiting

Gedatolisib plus drug combination for HR‑positive, HER2‑negative advanced breast cancer patients whose disease progressed after CDK4/6 inhibitor therapy

Registered drugNo placebo

Gedatolisib plus drug combination for HR‑positive, HER2‑negative advanced breast cancer patients whose disease progressed after CDK4/6 inhibitor therapy

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Alpelisib
Sponsor:Celcuity Inc.

Contact Research Centre

Chronic rhinosinusitis with nasal polyps

Not recruiting

Long‑term safety and tolerability of itepekimab in adults with inadequately controlled chronic rhinosinusitis with nasal polyps: an extension study

Investigational

Long‑term safety and tolerability of itepekimab in adults with inadequately controlled chronic rhinosinusitis with nasal polyps: an extension study

Investigational

France

Participants:18–64 years · 65+ years
Substances:Itepekimab
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Skin wrinkling

Not recruiting

Corabotase for Moderate to Severe Glabellar Lines in Adults

Investigational

Corabotase for Moderate to Severe Glabellar Lines in Adults

Investigational

France

Participants:18–64 years · 65+ years
Sponsor:Ipsen Innovation

Contact Research Centre

Small cell lung cancer extensive stage

Not recruiting

Study of Lutetium (177Lu) Oxodotreotide, Carboplatin, Etoposide, and Atezolizumab in Newly Diagnosed Extensive Stage Small Cell Lung Cancer Patients

Registered drugNo placebo

Study of Lutetium (177Lu) Oxodotreotide, Carboplatin, Etoposide, and Atezolizumab in Newly Diagnosed Extensive Stage Small Cell Lung Cancer Patients

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Atezolizumab
Sponsor:Novartis Pharma AG

Contact Research Centre

Systemic sclerosis pulmonary

Not recruiting

Tulisokibart in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease

Investigational

Tulisokibart in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease

Investigational

France

Participants:18–64 years · 65+ years
Substances:Tulisokibart
Sponsor:Prometheus Biosciences Inc.

Contact Research Centre

Rheumatoid arthritis

Not recruiting

Baricitinib Compared with Adalimumab and Etanercept in Patients with Rheumatoid Arthritis

Registered drugNo placebo

Baricitinib Compared with Adalimumab and Etanercept in Patients with Rheumatoid Arthritis

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Adalimumab
Sponsor:Eli Lilly & Co.

Contact Research Centre

Choroidal neovascularisation

Not recruiting

Faricimab for Choroidal Neovascularization Secondary to Pathologic Myopia in Patients with Pathologic Myopia

Registered drugNo placebo

Faricimab for Choroidal Neovascularization Secondary to Pathologic Myopia in Patients with Pathologic Myopia

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Faricimab
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Other cities in France

The busiest research cities in the country

All 376 cities in France

Clinical research in Clichy

What the registry says about research in the country

01 Gastrointestinal Disorders

Innovative trials focusing on inflammatory bowel diseases and advanced treatment methods, including studies on Crohn's disease and ulcerative colitis using fecal microbiota transplantation as therapeutic approaches.

Crohn's Disease Management
Ulcerative Colitis Treatment
Short Bowel Syndrome

Research aims to improve patient outcomes through novel therapeutic interventions and treatment strategies.

02 Hepatobiliary Research

Comprehensive studies on liver diseases and biliary tract conditions, investigating new treatments for cirrhosis, portal hypertension, and various forms of liver cancer.

Hepatocellular Carcinoma
Biliary Tract Cancer
Liver Cirrhosis

Advanced therapeutic approaches combining immunotherapy and targeted treatments.

03 Pancreatic and Metabolic Disorders

Groundbreaking research on pancreatic cancer and metabolic conditions, evaluating novel drug combinations and treatment protocols.

Pancreatic Adenocarcinoma
Neuroendocrine Tumors
Metabolic Liver Disease

Focus on improving survival rates and treatment efficacy in advanced-stage diseases.

Back to France All countries